PSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the treatment of type 2 diabetes. PSN9301 has a very rapid onset and a relatively... PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for meal-related dosing.
- Mechanism
- Curator reviewed
PSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), an enzyme involved in the inactivation of the gut hormone glucagon-like peptide-1 (GLP-1). GLP-1 plays an important role in regulating meal-related blood glucose by increasing the amount of insulin secreted in response to meals. PSN9301 increases GLP-1 activity and causes significant lowering of blood glucose levels. The increase in insulin secretion in response to GLP-1 is glucose-dependent, providing a built in safety mechanism against low blood glucose levels (hypoglycaemia) in response to treatment with DP-IV inhibitors.
- Primary indication
- Investigated for use/treatment in diabetes mellitus type 1 and 2.Curator reviewed
- Code names
- PSN9301
Resolves to
What you can answer from here — as of October 01, 2026
Which drugs share a target with PSN9301, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account